NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy

( Nasdaq:NK ), a leading, clinical-stage, natural killer cell based therapeutics company, today announced the launch of a novel triple combination, phase II clinical trial in Merkel cell carcinoma (MCC).